Data updated: Mar 10, 2026
POMALIDOMIDE
POMALIDOMIDE
Approved 2020-10-30
5
Indications
--
Phase 3 Trials
5
Years on Market
Details
- Status
- None (Tentative Approval)
- First Approved
- 2020-10-30
- Routes
- ORAL
- Dosage Forms
- CAPSULE
POMALIDOMIDE Approval History
Loading approval history...
What POMALIDOMIDE Treats
5 FDA approvalsOriginally approved for its first indication in 2020 . Covers 5 distinct patient populations.
- Other (5)
Other
(5 approvals)- • Approved indication (Oct 2020)Letter
- • Approved indication (Jan 2022)
- • Approved indication (May 2022)
- • Approved indication (Jun 2024)
- • Approved indication (Sep 2024)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
POMALIDOMIDE FDA Label Details
ProWant competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.